News

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...
Applied Clinical Trials Online3d

Phase III VAYHIT2 Trial Demonstrates Ianalumab Plus Eltrombopag Extends Disease Control in Primary Immune Thrombocytopenia

In the Phase III VAYHIT2 trial, ianalumab combined with eltrombopag significantly prolonged time to treatment failure and ...
InvestorsHub on MSN3d

Novartis shares edge higher after ianalumab hits key goals in Phase 3 trial

Novartis (NYSE:NVS) announced that its investigational antibody, ianalumab, combined with eltrombopag, successfully met the ...
TipRanks on MSN3d

Novartis ianalumab Phase III trial meets primary endpoint in ITP

Novartis (NVS) announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary ...
pharmaphorum3d

Novartis two for two as ianalumab scores again

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

Novartis shares slightly up after Ianalumab meets goals in Phase 3 trial

Novartis (NYSE:NVS) (SIX:NOVN) said its experimental antibody ianalumab, used in combination with eltrombopag, achieved the ...
MPR3d

Ianalumab Significantly Prolongs Time to Treatment Failure in Primary ITP

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...
Taiwan News3d

Novartis ianalumab Phase III trial meets primary endpoint in ITP ...

VAYHIT2 (NCT05653219) is a Phase III, multi-center, randomized, double-blind study evaluating the efficacy and safety of two different doses of ianalumab versus placebo, in addition to eltrombopag, in ...

Novartis Pharma AG: Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients ...